Target species
Cats.
Indications for use for each target species
For the treatment of gastrointestinal roundworms and tapeworms:
Toxocara cati, Toxascaris leonina, Dipylidium caninum, Taenia taeniaeformis.
Contraindications
Do not use simultaneously with piperazine compounds as piperazine may block the action of pyrantel embonate contained in the product. Other worming products may contain piperazine.
Do not use simultaneously with other deworming products without veterinary advice.
Do not use in kittens less than 6 weeks of age.
Do not use during pregnancy.
Do not use in animals with known hypersensitivity to the active substance or to any of the excipients.
Special warnings
Fleas serve as intermediate hosts for one common type of tapeworm - Dipylidium caninum. Tapeworm infestation is certain to re-occur unless control of intermediate hosts such as fleas, mice etc is undertaken.
Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:
- Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
- Underdosing, due to underestimation of body weight or misadministration of the product.
As a precautionary measure to prevent the establishment of Echinococcus multilocularis in the UK, it is recommended that all dogs and cats entering the country be treated with praziquantel.
Special precautions for use
Special precautions for safe use in the target species:
Not applicable.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
In the interests of good hygiene, persons administering the tablets directly to a cat, or by adding them to the cat’s food, should wash their hands afterwards.
Any part-used tablets should be discarded.
Special precautions for the protection of the environment:
Not applicable.
Adverse events
Cats:
Very rare (<1 animal / 10,000 animals treated, including isolated reports): | Digestive tract disorder1 (hypersalivation1, vomiting1) Neurological disorder1 (ataxia1) |
1Mild and transient
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Use during pregnancy, lactation or lay
Pregnancy and lactation
Do not use during pregnancy.
May be used during lactation.
Interaction with other medicinal products and other forms of interaction
Do not use simultaneously with piperazine compounds as piperazine may block the action of pyrantel embonate contained in the product. Other worming products may contain piperazine.
Administration routes and dosage
For oral use
Dosage
The recommended dose rates are: 57.5 mg/kg pyrantel embonate and 5 mg/kg praziquantel. This is equivalent to 1 tablet per 4 kg bodyweight.
Underdosing could result in ineffective use and may favour resistance development.
To ensure administration of the correct dose, body weight should be determined as accurately as possible.
Weight of cat
Up to 2 kg*: | 1/2 tablet |
greater than 2 kg up to 4 kg: | 1 tablet |
greater than 4 kg up to 6 kg: | 1½ tablets |
greater than 6 kg: up to 8kg: | 2 tablets |
* Do not administer to kittens less than 6 weeks of age.
If your cat weighs 6 kg or more, Drontal Cat XL Film-coated Tablets are available.
Administration and Duration of Treatment
Single oral administration. The tablet should be given directly to the animal, but if necessary can be disguised in food.
The need for and frequency of re-treatment(s) should be based on professional advice and should take into account the local epidemiological situation and the animal’s lifestyle.
Symptoms of overdose
No information.
Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance
Not applicable.
Withdrawal periods
Not applicable.